Imaging With a New Agent That Finds a Cancer Protein Called HER2
NCT03109977
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
6
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Carcinoma
HER2-positive Primary Malignancy
Interventions
DRUG:
Zr-DFO-pertuzumab PET/CT
Sponsor
Memorial Sloan Kettering Cancer Center